2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
307
Lung Neoplasms
111
Pancreatic Neoplasms
70
Neoplasms
56
Neoplasm Metastasis
32
Brain Neoplasms
31
Head and Neck Neoplasms
26
Squamous Cell Carcinoma of Head and Neck
25
Breast Neoplasms
25
Glioblastoma
24
Adenocarcinoma of Lung
23
Gliosarcoma
22
Non-Squamous Non-Small Cell Lung Cancer
21
Colorectal Neoplasms
18
Carcinoma, Hepatocellular
17
Adenocarcinoma, Bronchiolo-Alveolar
16
Rectal Neoplasms
13
Colonic Neoplasms
13
Carcinoma, Renal Cell
13
Glioma
12
Esophageal Neoplasms
11
Astrocytoma
11
Central Nervous System Neoplasms
9
Carcinoma, Squamous Cell
9
Salivary Gland Neoplasms
8
Prostatic Neoplasms
8
Oligodendroglioma
8
Gallbladder Neoplasms
8
Adenocarcinoma
8
Ovarian Neoplasms
7
Interventions
Dexamethasone
111
Cyclophosphamide
99
Melphalan
91
Bortezomib
69
Peripheral Blood Stem Cell Transplantation
64
Lenalidomide
58
fludarabine phosphate
56
Busulfan
54
Filgrastim
50
Tacrolimus
38
Antilymphocyte Serum
38
Thalidomide
36
Radiotherapy
36
Mycophenolic Acid
33
fludarabine
28
Cyclosporine
26
Methotrexate
25
Etoposide
22
Calcium Dobesilate
22
Whole-Body Irradiation
21
Prednisone
21
Methylprednisolone
20
sargramostim
19
pomalidomide
19
Granulocyte Colony-Stimulating Factor
18
carfilzomib
16
daratumumab
15
Cord Blood Stem Cell Transplantation
15
Carmustine
14
Rituximab
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Plasma Cell
×
Erlotinib Hydrochloride
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled